Geukens, Tatjana
De Schepper, Maxim
Van Den Bogaert, Wouter http://orcid.org/0000-0002-5803-3409
Van Baelen, Karen http://orcid.org/0000-0002-5700-3574
Maetens, Marion
Pabba, Anirudh
Mahdami, Amena http://orcid.org/0000-0002-3226-6933
Leduc, Sophia
Isnaldi, Edoardo
Nguyen, Ha-Linh http://orcid.org/0000-0002-2538-7657
Bachir, Imane
Hajipirloo, Maysam
Zels, Gitte
Van Cauwenberge, Josephine http://orcid.org/0000-0001-9802-186X
Borremans, Kristien http://orcid.org/0000-0001-7047-1543
Vandecaveye, Vincent
Weynand, Birgit
Vermeulen, Peter
Leucci, Eleonora http://orcid.org/0000-0002-2898-748X
Baietti, Maria Francesca http://orcid.org/0000-0002-1495-226X
Sflomos, George http://orcid.org/0000-0003-2972-0549
Battista, Laura http://orcid.org/0000-0002-9370-6736
Brisken, Cathrin http://orcid.org/0000-0002-6857-3230
Derksen, Patrick W. B.
Koorman, Thijs http://orcid.org/0000-0002-6064-3353
Visser, Daan
Scheele, Colinda L. G. J. http://orcid.org/0000-0001-8999-5451
Thommen, Daniela S.
Hatse, Sigrid
Fendt, Sarah-Maria http://orcid.org/0000-0001-6018-9296
Vanderheyden, Evy
Van Brussel, Thomas
Schepers, Rogier
Boeckx, Bram
Lambrechts, Diether http://orcid.org/0000-0002-3429-302X
Marano, Giuseppe
Biganzoli, Elia http://orcid.org/0000-0003-1202-5873
Smeets, Ann http://orcid.org/0000-0002-5091-6602
Nevelsteen, Ines
Punie, Kevin http://orcid.org/0000-0002-1162-7963
Neven, Patrick
Wildiers, Hans http://orcid.org/0000-0001-8990-7837
Richard, François http://orcid.org/0000-0003-4353-3619
Floris, Giuseppe http://orcid.org/0000-0003-2391-5425
Desmedt, Christine http://orcid.org/0000-0002-5223-5579
Article History
Received: 27 September 2023
Accepted: 5 April 2024
First Online: 24 April 2024
Competing interests
: T.G., M.D.S., W.V.D.B., K.V.B., M.M., A.P., A.M., S.L., E.I., H-L.N., I.B., M.H., G.Z., J.V.C., K.B., V.V., B.W., P.V., E.L., M.F.B., G.S., L.B., C.B., P.W.B.D., T.K., D.V., C.L.G.J.S., D.S.T., S.H., E.V., T.V.B., R.S., B.B., D.L., G.M., E.B., A.S., I.N., K.P., P.N., H.W., F.R., G.F., C.D.: no competing financial or non-financial interests to declare. S.M.F.: has received funding from Gilead, Black Belt Therapeutics and Alesta Therapeutics, has consulted for Fund+ and is in the advisory board of Alesta Therapeutics but declares no non-financial competing interests.